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Intratumorally (IT) administered INT230-6 (a combina-
tion of cisplatin, vinblastine and an amphiphilic cell
penetration excipient) induces complete responses (CR)
in large established tumors, durable protection against
re-inoculation, and the ability to shrink and/or resolve
non-treated bystander lesions. This therapy results in
massive cell death, and recruitment of lymphocytes and
DCs into the tumor. Here we explore combinations with
checkpoint inhibitors and investigate mechanisms for
protection from re-inoculation.
Cohorts of 10 BALB/c mice were inoculated with
1x106 Colon26 cells subcutaneously. Tumors were
grown to a mean of 325mm3 and then treated with
INT230-6 IT daily for 5 days (1 cycle) alone or in com-
bination with checkpoint inhibitors. Control arms
included no treatment, and the combination of anti-
CTLA4 and anti-PD-1 without drug. Multiple pairwise
comparisons were made. INT230-6 x1 was more effec-
tive than either control group. Three treatments with
INT230-6 tripled the fraction of CRs (from 10 to 30%).
Combination with anti-CTLA4 did not add benefit
beyond INT230-6 alone. The combination of INT230-6
x1 with anti-PD1 concurrently was more effective than
sequentially (50% vs 30% CR and median overall survival
(OS) not reached at 99 days vs 44 days). A third (3-way)
comparison was adding either anti-PD1 or anti-CTLA4
or both to the INT230-6 x 1 regimen concurrently.
INT230-6 with concurrent anti-PD-1 with or without
anti-CTLA4 were equivalent and resulted in high CR
rates (>50%) and significant prolongation of OS (> 99
days). Both were better than the combination with anti-
CTLA4 alone (20% CR and 39-day median OS).
To determine the role of T cell immunity induced by
the therapy, all 19 CR animals were re-randomized 102
days after initial treatment to receive either a control
IgG, anti-CD4 or anti-CD8 to deplete those T cells, and
then re-challenged with the same tumor. Tumors were
spontaneously cleared in the IgG group (implying lasting
tumor immunity), while all CD8-depleted animals devel-
oped new tumors and only 20% of CD4-depleted ani-
mals developed tumors, implying that most of the
protective immunity was CD8+ T cell-mediated.
Together, these results suggest that INT230-6 and anti-
PD-1 given concurrently shows significant synergy and
can induce durable complete responses in these estab-
lished colorectal tumor models. The data support the
hypothesis that the mechanism of action of this therapy
includes induction of tumor specific memory (most
importantly CD8+) T cells that can address any regrowth
or distant metastases (the latter based on rejection of
contralateral tumors in our previous studies).
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